paclitaxel has been researched along with Ascites in 84 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (5.95) | 18.2507 |
| 2000's | 38 (45.24) | 29.6817 |
| 2010's | 37 (44.05) | 24.3611 |
| 2020's | 4 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Fushimi, A; Higaki, K; Kono, Y; Ogawara, KI; Yoshizawa, Y | 1 |
| Abbey, L; Abdelghany, TM; Abdellatif, MH; Abdelmohsen, UR; Abduljaleel Alzawar, NS; Abid, MF; Abu Kasim, AFB; Abu Saad, H; Adolpho, LF; Agostini, F; Agrizii, AP; Ahmed, S; Akce, M; Åkesson, D; Al-Awaadh, AM; Al-Mutar, DMK; Al-Odayni, AB; Al-Rajhi, AMH; Alaaeldin, R; Alam, M; Alam, MM; Alanazi, MA; Alattar, H; Alawlaqi, MM; Aldebis, HK; Algehainy, NA; Almeida, AA; Aloisi, F; Alrahlah, A; Alsenani, F; Alshabib, A; Altemani, FH; Althagafi, A; Amari, A; Andronesi, AG; Antonyuk, M; Arantes, TD; Araújo, R; Arrotti, S; Asakura, T; Asib, N; Atlaskin, AA; Aung, MS; Axiaq, A; Azekawa, S; Bacon, S; Bagalagel, A; Balbinot, GS; Barnet, LS; Baroyi, SAHM; Barreto, F; Barth, Y; Barysheva, AV; Bassa, E; Basu, R; Basu, S; Bates, C; Bautista, LS; Beitl, K; Beloti, MM; Benatti, G; Benavent-Celma, C; Bentaher, A; Bergsland, N; Bernardino, AF; Bernhardt, A; Bhandari, RK; Bhaskaran, K; Bhate, K; Bhattacharjee, A; Bian, X; Bien, EM; Birch, M; Bishara, K; Biswas, JP; Bleha, R; Bocale, R; Bona, S; Boriani, G; Bouyssi, A; Bradley, D; Bravo-Sánchez, MG; Bressan, GC; Brik, A; Brizuela, A; Brockbank, KGM; Buchner, F; Bunc, M; Buscombe, JR; Butler, AJ; Buzaleh, AM; Buzin, MI; Cabrera-Capetillo, CA; Calvo, AM; Camerota, A; Campagna, G; Campisi, M; Cano, K; Cao, HST; Cardellini, S; Carvalho, AP; Carvalho, BCR; Castillo-Baltazar, OS; Cataldo, P; Chai, P; Chakraborty, S; Chalo, DM; Chan, MY; Chander, S; Changbunjong, T; Chappuis, CJF; Chee, RCH; Chen, C; Chen, CJ; Chen, E; Chen, M; Chen, X; Chen, Y; Cheng, HT; Cheng, MC; Cheow, HK; Chi, Y; Chirikova, NK; Chiu, SH; Cho, G; Cho, HR; Cho, S; Cho, SJ; Choe, A; Choe, YH; Chun, BS; Chun, Z; Cinque, A; Ciopec, M; Cladas, Y; Cleary, SP; Clermont, O; Cléroux, M; Cockburn, J; Collares, FM; Colombini-Ishikiriama, BL; Conn, BN; Cortina, JL; Cox, DRA; Crini, G; Croker, R; Cursaru, DL; Curtis, HJ; da Silva, KJG; Dalla Costa, T; Davy, S; de Araújo, BV; de Cassia Ribeiro Gonçalves, R; de Gaetano, F; de Gregorio, C; de Oliveira, MG; De Vera, MAT; de Vos, M; de-la-Fuente, I; Dell'Oca, I; Delles, M; Déméautis, T; Dempster, M; Deng, YH; Denisenko, Y; Descombes, C; Desideri, G; Devarbhavi, H; Devouassoux, G; Di Bella, G; Di Marco, F; Diao, Y; Dias, BB; Dilgin, Y; Dimopoulou, I; Dionísio, TJ; Dobrovic, A; Dokin, ES; Dolby, T; Dong, X; Dong, Y; Dou, SX; Douglas, IJ; Dousset, S; Du, Z; Duan, M; Duan, SB; Duke-Williams, O; Duteanu, N; Dutertre, S; Dutta, S; Dwyer, MG; Ebenbauer, J; Eggo, RM; El-Mordy, FMA; Elbhnsawi, NA; Elrehany, MA; Elshewemi, SS; Elwakil, BH; Emadzadeh, D; Eraso, E; Ermolenko, E; Erten, K; Ettorre, E; Evans, D; Evans, SJ; Faheem, M; Fallanza, M; Faramarzi, M; Faria, FAC; Faro, DC; Fatma, YS; Fazil, S; Feng, Y; Ferguson, J; Fernandes, MH; Fernández-Domínguez, M; Ferrari, LAL; Ferraz, EP; Ferreira, LC; Ferri, C; Fikry, M; Floris, M; Forbes, H; Fotouh, B; Franke, K; Freitas, AC; Freitas, GP; Frieboes, HB; Fu, B; Fu, Y; Fukina, DG; Fukuda, DH; Fukunaga, K; Fulham, GJ; Furlan, L; Furtado Mesa, M; Furtunescu, FL; Gabbieri, D; Ganash, M; Gebers, JC; Gehman, V; Ghaedi, A; Ghazali, NSM; Ghebrekristos, Y; Gil, J; Gilbert, NM; Gimenes, R; Giordano, L; Glehen, O; Godeau, C; Goh, SK; Goldacre, B; Gomes, AM; Gomes, MPO; Gomes, PS; Gomes, RMODS; Gómez-Coma, L; Grenho, L; Gu, Q; Gu, T; Gu, YC; Guiducci, V; Guillemin, JP; Guo, W; Guo, YW; Gur, E; Guridi, A; Guzmán-López, A; Gvozdenko, T; H Elmaidomy, A; Hagar, M; Haider, S; Han, JM; Hanratty, J; Hans, R; Haque, N; Harharah, HN; Harharah, RH; Harper, S; Hasegawa, N; Hassanin, AH; Hastuti, YP; Hatem, AE; He, R; He, Y; Heinemann, C; Heinmaa, I; Heinzl, F; Helfer, VE; Hester, F; Hickman, G; Hill, MA; Hill, WG; Hintze, V; Ho, JSY; Ho, LY; Hoang, T; Holzer, I; Houbraken, J; Hsu, CN; Hu, J; Hu, X; Hu, Y; Hua, T; Huang, Z; Hulme, WJ; Hunter, A; Ianăşi, C; Ibañez, R; Iezzi, R; Iliuță, L; Im, YM; Imran, M; Inglesby, P; Inguimbert, N; Iqbal, A; Izawa, N; Jahaj, E; Jain, S; Jakimovski, D; Jalal, MM; Jaroszuk-Ściseł, J; Jasim, DJ; Jauregizar, N; Javle, MM; Jędryczka, M; Ji, H; Jiang, Y; Jin, J; Johnson, NT; Joshi, S; Jullok, N; Kachapulula, PW; Kaczmarek, J; Kaczmarek-Szczepańska, B; Kadota, K; Kaji, M; Kakeji, Y; Kakizoe, S; Kakudidi, E; Kalitukha, L; Kamata, H; Kang, YJ; Kapinos, AA; Karakaya, S; Kashchenko, NI; Kasyanov, S; Kataky, R; Katati, B; Kato, G; Katsina, AU; Kaya, A; Kaya, H; Kazarina, OV; Ke, Y; Keenan, C; Keilson, JM; Keshavan, A; Keskinidou, C; Khalifa, MA; Khan, R; Khan, S; Kim, D; Kim, K; Kim, MS; Kim, SM; Kim, WH; Kim, Y; Kim, YJ; Kishimura, H; Kitagawa, RR; Klemenkova, ZS; Kloss, F; Kobayashi, N; Kohlhoff, M; Kong, WKF; Konsek, H; Kornaros, M; Kotanidou, A; Kovacs, S; Kraska, J; Kruppke, B; Kumagai, Y; Kumar, S; Kumari, R; Kuruva, V; Kuster, RM; Kusumoto, T; Kutyła, M; Kwon, JH; Kwon, SH; Kwong, KY; Kyser, AJ; Lackner, M; Lass-Flörl, C; Lauri, C; Lavandera, JV; Lee, BH; Lee, ECY; Lee, HJ; Lee, J; Lee, PS; Lee, S; Lee, SE; Lee, SY; Lefort, F; Leite, JPV; Leo, G; Leonard, R; Leow, AST; Lepori, N; Leyden, K; Leys, L; Ležaić, L; Li, D; Li, H; Li, J; Li, S; Li, TYW; Li, X; Li, XH; Li, Y; Li, Z; Li, ZH; Liao, S; Liaqat, K; Lim, H; Lin, BS; Lin, MY; Lin, NH; Lin, X; Lin, Y; Liu, C; Liu, H; Liu, HK; Liu, HX; Liu, P; Liu, R; Liu, T; Liu, X; Liu, Y; Lock, GA; Lokaj, G; Lopes, HB; Losi, V; Lotsios, NS; Low, KE; Lu, Z; Luhana, S; Luo, X; Luo, XQ; Lutz, MB; Lysova, AA; Lyssenko, KA; Macit, M; MacIver, B; MacKenna, B; Magalhães, GAP; Magnavacchi, P; Mahadevan, J; Mahboubi, A; Maher, SA; Mahipal, A; Mahmoud, MY; Maithel, SK; Makhtar, MMZ; Makurat-Kasprolewicz, B; Malysheva, YB; Mansourizadeh, A; Marek, EJ; Maresca-Fichter, H; Martin, JT; Maslov, AA; Mastora, Z; Mastroiacovo, D; Mastropetros, SG; Matei, D; Mathur, R; Matos, AO; Matsuda, Y; Maurya, SK; Mayor, Á; Mayrhofer, D; Mazzuco, AC; McCaffrey, J; McClure, T; McDonald, HI; Mchunu, NP; McLaggan, D; Mehrkar, A; Meilik, B; Melito, VA; Mellem, J; Mengozzi, A; Menotti, J; Mesquita, V; Miao, Z; Mihai, S; Miller, S; Minassian, C; Mirabile, A; Mitra, S; Mladin, G; Mo, Z; Moawad, H; Mohamed, EM; Mohammed, TJ; Mohanlall, V; Mohyeldin, RH; Moldovan, H; Monneret, G; Monopoli, DE; Monte, IP; Monteiro, JRB; Morgante, V; Mori, M; Morin-Crini, N; Morita, A; Morton, CE; Mrak, M; Muhammed, AP; Mulick, A; Muralidharan, V; Murthy, P; Muselli, M; Mustafa, S; Mysore Visweswariah, A; Nagao, G; Naicker, S; Nakagawara, K; Namgoong, B; Namkoong, H; Namukobe, J; Nasir, AA; Nasreen, SA; Natarajan, P; Nchiozem-Ngnitedem, VA; Necozione, S; Negrea, A; Negrea, P; Ngubane, S; Nguyen, TT; Nicke, A; Nightingale, E; Nistor, CL; Nitsch, D; Njapau, H; Noman, M; Novgorodtseva, T; Nowak, A; O'Connor, SR; Ofoe, R; Oh, K; Oh, TH; Oki, E; Olama, ZA; Olennikov, DN; Oliveira, GM; Omar, D; Ong, SJ; Orfanos, SE; Origa-Oryem, H; Orita, H; Ortiz, I; Ota, M; Ott, J; Otvagina, KV; Pacheco, N; Pacheco, RR; Padmanabhan, D; Pagan, JD; Pagnotta, PA; Palangi, V; Palanisamy, G; Palanisamy, K; Palanisamy, S; Pan, SG; Panaitescu, E; Pang, X; Panoutsakopoulos, V; Parera, VE; Park, JI; Park, JS; Park, SW; Park, Y; Park, YS; Parkash, O; Parry, J; Parry, JP; Paul, SK; Pavšič, N; Pałubicka, A; Persat, F; Petriz-Prieto, MA; Petukhov, AN; Pham, T; Pillay, S; Poh, KK; Ponomarev, II; Pontons-Melo, JC; Posa, A; Powell, E; Priya, AK; Punekar, R; Puppin Rontani, RM; Purushottam, M; Pusphanathan, K; Qi, JY; Qin, J; Qin, Z; Qiu, B; Qiu, X; Quattrini, G; Quindós, G; Qureshi, F; Rabbany, MA; Rac-Albu, M; Rac-Albu, ME; Rădulescu, BC; Rafatullah, M; Rajab, TK; Rajna, S; Ramanathan, M; Rao, D; Raviglione, D; Razorenov, DY; Redd, MJ; Rehman, W; Reig, M; Rentsch, CT; Ribeiro, LMS; Robles, D; Rocchi, S; Rocha, FG; Rodrigues, C; Rodrigues, LA; Rodrigues, RP; Roh, GH; Ronowska, A; Root, A; Rosa, AL; Rossi, R; Roy, S; Roy, VC; Rupji, M; Saber, EA; Sadarat, F; Saed, Y; Saeed, WS; Saeki, H; Saha, B; Saiwichai, T; Sakowicz-Burkiewicz, M; Sampedro, T; Sands, K; Santos, CF; Sari, M; Sathi, FA; Sauro, S; Sazanova, TS; Scafa-Udriște, A; Schoustra, SE; Schultze, A; Seo, DJ; Sevillano, E; Sezmis, G; Sgura, FA; Shah, NNAK; Shani, N; Shankarappa, B; Sharkey, LM; Sharma, VK; Sharp, C; Shehata, N; Shelton, N; Shieh, PB; Shimokawa, M; Shin, J; Shin, SH; Shin, YN; Shin, YR; Shipilova, A; Shoparwe, NF; Shukor, H; Sia, CH; Siddiqui, MH; Siddiqui, MR; Siena, V; Signore, A; Silwane, B; Siqueira-Sandrin, VS; Siregar, A; Sirignano, P; Sit, NW; Skidmore, S; Skupov, KM; Smeeth, L; Smoczer, C; Smolyanskiy, E; Sohn, H; Solodeev, I; Solovyev, A; Şomoghi, R; Song, F; Song, H; Song, Z; Souf, YM; Sousa, SC; Souza, MT; Steinbach-Rankins, JM; Stockton, J; Stout, JR; Su, K; Su, MZ; Suarez-Lopez, YA; Sukkurd, R; Sultanov, R; Sun, Y; Sun, Z; Supernak, M; Supriyono, E; Suroshe, SS; Suvorov, SS; Svera M Ianăşi, P; Switchenko, JM; Syarif, NY; Synytsya, A; Taherzadeh, MJ; Tain, YL; Tamburino, C; Tammam, OY; Tan, BYQ; Tan, H; Tan, S; Tanaka, H; Tang, R; Tang, X; Tang, Z; Taurino, M; Tazare, J; Teresi, L; Testro, A; Thanasoponkul, W; Thangarasu, S; Thavaselvam, D; Theodoro, RC; Theron, G; Thomas, RH; Thomson, JJ; Tian, X; Tian, Y; Tomaszewski, CA; Tomlinson, LA; Torres, CMME; Tóth, M; Trecourt, A; Trevisani, F; Trimarchi, G; Tristán, C; Truong, VK; Tsigkou, K; Tsutsumi, S; Ubukata, Y; Uehara, H; Uwamino, Y; Vahedi-Shahandashti, R; Valberg, SJ; Valderrama, C; Valdovinos-García, EM; Valsecchi, D; van Diepeningen, AD; van West, P; Vargas-Osuna, E; Vassall, M; Vassilaki, N; Vassiliou, AG; Vecino, X; Velez-Irizarry, D; Venkatesh, YN; Vignali, L; Virdis, A; Viswanath, B; Voisin, AS; Volkova, YA; Vorotyntsev, AV; Vorotyntsev, IV; Vtyurina, ES; Vu, DH; Waldridge, B; Walker, AJ; Wallon, M; Wang, B; Wang, G; Wang, H; Wang, J; Wang, LJ; Wang, S; Wang, T; Wang, X; Wang, Z; Warren, RM; Warren-Gash, C; Wei, SH; Weinstock-Guttman, B; Wekwejt, M; Wessjohann, LA; Wiesmann, HP; Williams, ZJ; Williamson, EJ; Wilson, M; Wing, K; Wong, AY; Wong, BKL; Woodward, S; Wozniak, KL; Wu, C; Wu, K; Wu, S; Wu, Y; Xiang, D; Xie, H; Xiong, X; Xu, C; Xu, H; Xu, J; Xu, WH; Xu, Y; Xun, T; Yamaguchi, S; Yan, P; Yan, W; Yan, Z; Yang, B; Yang, F; Yang, L; Yao, XB; Yasui, H; Yenesew, A; Yeo, LLL; Yeo, TC; Yi, S; Yin, F; Yip, JWL; Yoon, SH; Yoon, SJ; Yoshida, M; Yoshizumi, T; Young, LA; Yu, C; Yu, DD; Yu, F; Yu, H; Yu, JD; Yu, NJ; Yu, X; Yuan, Y; Yurenko, A; Yusof, YA; Zahedipoor, A; Zahran, EM; Zainuddin, NI; Zanatta, AC; Zanotto, ED; Zanozin, ID; Zavascki, AP; Zenke, M; Zhang, F; Zhang, G; Zhang, H; Zhang, J; Zhang, L; Zhang, MX; Zhang, NY; Zhang, Q; Zhang, W; Zhang, X; Zhang, XM; Zhao, F; Zhao, Q; Zhao, R; Zhao, Y; Zheng, J; Zheng, S; Zhou, L; Zhou, X; Zhu, H; Zivadinov, R; Žižek, D; Zuccoli, JR; Zwaan, BJ | 1 |
| Au, JLS; Chan, CHF; Lu, Z; Turaga, K; Wientjes, MG | 1 |
| Hashimoto, Y; Hirahara, S; Kobayashi, H; Kubota, H; Kuhara, Y; Miyamoto, K; Sakashita, Y; Shirakawa, K; Toyota, K; Yano, R; Yokoyama, Y | 1 |
| Anttila, M; Hämäläinen, K; Hytönen, E; Karvonen, A; Kosma, VM; Laakso, H; Liimatainen, T; Sallinen, H; Tuppurainen, L; Valkonen, E; Ylä-Herttuala, S | 1 |
| Chen, Y; Teng, NNH; Westhoff, GL | 1 |
| Ando, Y; Hato, Y; Ito, Y; Kawaguchi, Y; Nishikawa, S; Sugiura, H; Terada, M; Yoshimoto, N | 1 |
| Bando, H; Doi, T; Fukuoka, S; Kawazoe, A; Kojima, T; Kuboki, Y; Matsumoto, H; Ohtsu, A; Shimada, K; Shitara, K; Yoshino, T | 1 |
| Chen, J; Ding, Y; Ma, L; Zhang, L; Zhuang, Y | 1 |
| Kasahara, K; Nishi, K; Okazaki, A | 1 |
| Kaye, SB; Kipps, E; Tan, DS | 1 |
| Boyle, GM; Clements, JA; Dong, Y; Harris, JM; McGuckin, MA; Parsons, PG; Stephens, C; Swedberg, JE; Walpole, C | 1 |
| Amm, HM; Buchsbaum, DJ; DellaManna, D; Egger, ME; Eltoum, IE; Frederick, PJ; Grizzle, WE; Kerr, EH; McNally, LR; Oelschlager, DK; Sellers, J; Stockard, CR; Straughn, JM | 1 |
| Emoto, S; Ishigami, H; Kaisaki, S; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H | 1 |
| Enomoto, N; Hamaguchi, T; Honma, Y; Iwasa, S; Kadokura, M; Kato, K; Shimada, Y; Yamada, Y | 1 |
| Ebisui, C; Fukuchi, N; Kato, R; Kinuta, M; Makino, S; Murata, K; Okada, K; Okamura, S; Takeoka, T; Wada, Y; Yanagisawa, T; Yokouchi, H | 1 |
| Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y | 1 |
| Chen, X; Hu, M; Xie, C; Xu, F; Xue, S; Zhang, A; Zhao, J | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H | 1 |
| Bale, LK; Becker, MA; Conover, CA; Haluska, P; Oxvig, C | 1 |
| Castelo, B; Espinosa, E; Pinto, A; Redondo, A; Zamora, P | 1 |
| Akita, H; Hayasaka, J; Kondo, M; Kusano-Kitazume, A; Ohtaka, Y; Okamoto, E; Shibayama, T; Suenobu, Y; Takagi, K; Tamura, A; Tei, S; Watanabe, A | 1 |
| Fujii, K; Iwai, N; Kataoka, K; Masuzawa, A; Matsumoto, N; Morita, Y; Takada, R; Takami, S; Takaya, H; Tanaka, N; Wakabayashi, N; Yoriki, H | 1 |
| Emoto, S; Hanafusa, N; Ishigami, H; Ito, T; Kitayama, J; Watanabe, T; Yamaguchi, H | 1 |
| Bachelder, RE; Bryja, V; Cianciolo, GJ; Huang, Z; Kennedy, M; Mo, L; Murphy, SK; Payne, S; Pizzo, SV; Pospichalova, V; Wang, F | 1 |
| Burger, RA; Cohn, DE; Duska, LR; Java, JJ | 1 |
| Fushida, S; Hayashi, H; Hirakawa, K; Kinoshita, J; Miyashita, T; Ninomiya, I; Ohbatake, Y; Ohta, T; Oyama, K; Tajima, H; Takamura, H; Tsukada, T; Yashiro, M | 1 |
| Isayama, H; Ishigami, H; Kitayama, J; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Satoi, S; Tada, M; Takahara, N; Watanabe, T; Yamaguchi, H; Yamamoto, N | 1 |
| Bach, BA; Bae, DS; Bamias, A; Brize, A; Coleman, RL; Fabbro, M; Fujiwara, K; Karlan, BY; Lhommé, C; Ma, H; Marth, C; Monk, BJ; Oaknin, A; Oza, AM; Poveda, A; Provencher, DM; Raspagliesi, F; Ray-Coquard, I; Redondo, A; Richardson, G; Rincón, DG; Vergote, I; Vogl, FD | 1 |
| Barakova, NV; Bespalov, VG; Maidin, MA; Semenov, AL; Stukov, AN; Vasil'eva, IN; Vyshinskaya, EA | 1 |
| Hoshino, H; Hosoda, Y; Kawada, J; Kim, Y; Nagai, K; Nishino, M; Okano, M; Okuyama, M; Tsujinaka, T | 1 |
| Kesterson, JP; Lele, S; Mhawech-Fauceglia, P | 1 |
| Jänsch, A; Pandey-Hoffmann, U; Pflugbeil, C; Schlodder, D; Schrag, S; Stange, R; Uehleke, B | 1 |
| Anwer, K; Brunhoeber, E; Fewell, JG; Lewis, DH; Matar, MM; Pence, C; Rice, JS; Slobodkin, G; Worker, M | 1 |
| Ito, C; Kamijo, Y; Miyamoto, K; Nomura, M; Sai, Y | 1 |
| Alvero, AB; Kim, KH; Mor, G; Tytler, EM; Woessner, R; Xie, Y | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Sakamoto, T; Shimoyama, R; Taku, K; Todaka, A; Tomita, H; Tsushima, T; Yamazaki, K; Yasui, H | 1 |
| Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H | 1 |
| Boku, N; Fukutomi, A; Kojima, T; Machida, N; Onozawa, Y; Shukuya, T; Taku, K; Yamazaki, K; Yasui, H | 1 |
| Chang, JS; Chen, CA; Chen, MW; Hsiao, M; Hsiao, SM; Kuo, ML; Lai, TC; Lo, CW; Rose-John, S; Wang, S; Wei, LH | 1 |
| Iishi, H; Imamoto, H; Kakutani, C; Morimoto, T; Morita, S; Nakamura, M; Narahara, H; Oba, K; Oriuchi, N; Sakamoto, J; Shiozaki, H; Yumiba, T | 1 |
| Choi, EK; Kang, MH; Kim, SW; Kim, YT; Nam, EJ; Paek, J; Yim, GW | 1 |
| Ishikawa, H; Iwazaki, S; Izumi, M; Kakinuma, S; Kamoshita, N; Kawate, S; Kobayashi, I; Kobayashi, J; Makita, F; Nakagami, K; Ohya, T; Okabe, T; Sakamoto, I; Sato, Y; Sunose, Y; Takeyoshi, I; Tanahashi, Y; Tomizawa, N; Yamada, T; Yoshinari, D | 1 |
| Kodama, M; Mekata, E; Okumura, K; Shiogai, Y; Tan, T; Tani, S | 1 |
| Fuse, N; Goto, M; Hironaka, S; Iwasa, S; Kusaba, H; Nakajima, TE; Nakayama, N; Nishina, T; Shimada, Y; Taira, K; Takahari, D; Yasui, H | 1 |
| Arcand, SL; Caceres, KY; Cyr, L; de Ladurantaye, M; Delvoye, N; Létourneau, IJ; Mes-Masson, AM; Meunier, L; Portelance, L; Provencher, DM; Quinn, MC; Shen, Z; Tonin, PN; Wang, LL | 1 |
| Bamba, M; Fujimoto, Y; Kaneko, C; Kobayashi, TK; Moritani, S; Urabe, M | 1 |
| Ezaki, T; Ikegami, T; Ishida, T; Itoh, H; Kawaguchi, K; Kido, A; Nose, N; Sasaki, Y; Shimokawa, H | 1 |
| Ferrara, N; Hamilton, T; Hofmann, J; Hu, L; Jaffe, RB; Zaloudek, C | 1 |
| Chiba, H; Hirayama, Y; Iyama, S; Nakajima, T; Niitsu, Y; Oku, T; Sagawa, T; Sakamaki, S; Sato, Y; Sumiyoshi, T; Takahashi, M; Takayama, T; Takayanagi, N; Tsuji, Y | 1 |
| Imamoto, H; Kinoshita, K; Morita, S; Nakane, Y; Narahara, H; Sakamoto, J; Shiozaki, H; Yumiba, T | 1 |
| Funai, S; Hirai, T; Kamei, A; Ohtsuka, H; Shindo, K; Shiozaki, H; Tanaka, A; Yoshifuji, T | 1 |
| Fujimitsu, Y; Kato, J; Kojima, H; Kojima, T; Matsui, T; Uemura, T | 1 |
| Inagaki, K; Kanayama, N; Kobayashi, H; Kondo, T; Suzuki, M; Terao, T; Yagyu, T | 1 |
| Furui, N; Furukawa, H; Fushida, S; Ishizaki, J; Jin, M; Miwa, K; Miyamoto, K; Nomura, M; Yamazaki, M; Yokogawa, K; Yoshihara, H | 1 |
| Bamba, M; Kobayashi, TK; Moritani, S; Muramatsu, M; Nishino, T; Ueda, M; Urabe, M | 1 |
| Fujimitsu, Y; Inagaki, H; Kato, J; Kojima, H; Kojima, T; Matsui, T; Sakamoto, J; Tanehiro, K; Uemura, T | 1 |
| Hayashidani, Y; Morifuji, M; Murakami, Y; Sasaki, M; Sueda, T; Toge, K; Yokoyama, Y | 1 |
| Miyade, Y; Ninomiya, M; Ohtani, S; Shimizu, Y; Sugiyama, S | 2 |
| Duivenvoorden, W; Matthews, D; Richard, C; Th'ng, JP; Wright, PS; Yau, J | 1 |
| Chijiiwa, K; Eto, TA; Hotokezaka, M; Iwamura, T; Shibata, N | 1 |
| Hofmann, J; Holash, J; Hu, L; Jaffe, RB; Sood, AK; Yancopoulos, GD | 1 |
| Ami, K; Andou, M; Ganno, H; Ichikawa, S; Ito, T; Kimu, K; Kobo, T; Nagahama, T; Nawa, K; Ohbu, M; Takaba, E; Yamauchi, A | 1 |
| Ebuchi, M; Hasegawa, K; Koide, A; Maruyama, M; Maruyama, S; Miyawaki, Y; Ohbu, M; Takashima, I; Tamura, N | 2 |
| Ikuta, Y; Kobayashi, H; Sugihara, S; Teshima, K; Toyama, E; Tsuruta, Y; Yonemitsu, K | 1 |
| Ge, ZQ; Liu, CX; Yang, WY; Yin, DS; Yuan, YJ | 1 |
| Araki, K; Ichikawa, K; Kobayashi, M; Namikawa, T; Okabayashi, T; Okamoto, K; Sakamoto, J | 1 |
| Chen, Q; Huang, Q; Jiang, W; Kang, Y; Li, B; Li, L; Lu, H; Xu, C | 1 |
| Hirakawa, K; Inoue, T; Kim, T; Kimura, K; Muguruma, K; Ohira, M; Sawada, T; Toyokawa, T; Yamashita, Y; Yashiro, M | 1 |
| Hara, A; Iwamoto, S; Izumi, N; Tsunemi, S; Yamamoto, M | 2 |
| Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Kondo, M; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohsato, H; Ohshiro, R; Ohta, K; Takemoto, H; Tatsuta, M; Yamamoto, K | 1 |
| Imai, S; Ito, T; Kawamoto, K; Morimoto, Y; Niwano, M; Ogasahara, K; Okabe, M; Paku, T; Sano, K; Tsuruta, A; Yamaguchi, K; Yoshida, Y | 1 |
| Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E | 1 |
| Allen, C; Cho, J; Grant, J; Ho, E; Lim Soo, P; Piquette-Miller, M | 1 |
| Dhabhar, B; Hazarika, N; Saikia, TK | 1 |
| Akrivos, T; Dertimas, V; Iavazzo, C; Kalinoglou, N; Katsoulis, M; Vorgias, G | 1 |
| D'Incalci, M; Giavazzi, R; Lucchini, V; Nicoletti, MI | 1 |
| Davison, JD; Francis, PA; Ganju, V; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC | 1 |
| de Boer-Dennert, M; Pronk, LC; Stoter, G; van Beurden, V; van Putten, WL; Verweij, J | 1 |
| Eltabbakh, GH; Hempling, RE; Intengen, ME; Piver, MS; Recio, FO | 1 |
| Cohen, Y; Horowitz, J; Meirovitz, M; Piura, B | 1 |
1 review(s) available for paclitaxel and Ascites
11 trial(s) available for paclitaxel and Ascites
| Article | Year |
|---|---|
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Catheter-Related Infections; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2014 |
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Body Mass Index; CA-125 Antigen; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Obesity; Ovarian Neoplasms; Paclitaxel; Patient Readmission; Peritoneal Neoplasms; Risk Factors; Time Factors | 2015 |
Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Parenteral; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2016 |
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Recombinant Fusion Proteins | 2016 |
Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ascites; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Quality of Life; Retrospective Studies; Treatment Failure; Treatment Outcome | 2010 |
Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Ascites; Ascitic Fluid; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Failure; Treatment Outcome; Waist Circumference | 2011 |
Weekly paclitaxel in combination with doxifluridine for peritoneally disseminated gastric cancer with malignant ascites.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Dose-Response Relationship, Drug; Female; Floxuridine; Humans; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Time Factors; Treatment Outcome | 2011 |
Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Disease-Free Survival; Drug Administration Schedule; Eating; Feasibility Studies; Female; Fluorouracil; Humans; Intestinal Perforation; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms | 2012 |
A phase II clinical trial to evaluate the effect of paclitaxel in patients with ascites caused by advanced or recurrent gastric carcinoma: a new concept of clinical benefit response for non-measurable type of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Ascites; Concept Formation; Drug Administration Schedule; Humans; Paclitaxel; Stomach Neoplasms | 2003 |
The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Ascites; Breast Neoplasms; Docetaxel; Edema; Humans; Hydroxyethylrutoside; Middle Aged; Paclitaxel; Pericardial Effusion; Pleural Effusion; Taxoids; Water-Electrolyte Imbalance | 1999 |
73 other study(ies) available for paclitaxel and Ascites
| Article | Year |
|---|---|
Effects of particle size and release property of paclitaxel-loaded nanoparticles on their peritoneal retention and therapeutic efficacy against mouse malignant ascites.
Topics: Animals; Ascites; Carcinoma; Cell Line, Tumor; Emulsions; Liposomes; Mice; Nanoparticles; Paclitaxel; Particle Size; Peritoneal Neoplasms; Quality of Life | 2022 |
Surgical management of peritoneal metastasis: Opportunities for pharmaceutical research.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Colorectal Neoplasms; Combined Modality Therapy; Humans; Hyperthermia, Induced; Paclitaxel; Peritoneal Neoplasms; Pharmaceutical Preparations; Pharmaceutical Research; Proteomics; Tandem Mass Spectrometry | 2023 |
[A Case of Unresectable Pancreatic Cancer with Massive Cancerous Ascites Responsive to KM-CART].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Female; Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms | 2021 |
Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carboplatin; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Female; Genetic Therapy; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Random Allocation; Receptor, TIE-2; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2017 |
Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Forkhead Box Protein M1; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Thiostrepton | 2017 |
[Three Poor Performance Status(PS)Cases of Metastatic Breast Cancer Controlled with Adjustment of Dosing Interval and Dosage of Bevacizumab and Paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Pleural Effusion; Treatment Outcome | 2017 |
A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Ascites; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Ramucirumab; Retrospective Studies; Stomach Neoplasms | 2018 |
A rare case report of ovarian juvenile granulosa cell tumor with massive ascites as the first sign, and review of literature: Case report and review of literature.
Topics: Abdominal Cavity; Antineoplastic Agents; Ascites; CA-125 Antigen; Chemotherapy, Adjuvant; Female; Granulosa Cell Tumor; Humans; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salpingo-oophorectomy; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography; Young Adult | 2018 |
Pseudo-Meigs syndrome caused by cancer of the uterine corpus.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carboplatin; Female; Humans; Hysterectomy; Meigs Syndrome; Neoplasms, Cystic, Mucinous, and Serous; Omentum; Paclitaxel; Pleural Effusion; Radiography, Thoracic; Salpingo-oophorectomy; Tomography, X-Ray Computed; Uterine Neoplasms | 2019 |
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Biomarkers, Tumor; Carboplatin; Drainage; Female; Humans; Ovarian Neoplasms; Paclitaxel; Paracentesis; Peritoneal Neoplasms; Peritoneum; Prognosis; Translational Research, Biomedical | 2013 |
Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.
Topics: Antineoplastic Agents; Ascites; Cell Line, Tumor; DNA Primers; Drug Resistance, Neoplasm; Female; Humans; Kallikreins; Ovarian Neoplasms; Paclitaxel; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Spheroids, Cellular; Tumor Microenvironment | 2013 |
Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Blotting, Western; Carboplatin; Cystadenocarcinoma, Serous; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Microfilament Proteins; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles | 2013 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Salvage Therapy; Stomach Neoplasms; Survival Rate; Tegafur | 2014 |
Weekly paclitaxel as second-line chemotherapy in Japanese patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Ascites; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2013 |
[A case of unresectable gastric cancer in a patient who maintained a good quality of life with multidisciplinary treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Brain Neoplasms; Combined Modality Therapy; Fatal Outcome; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Pyloric Stenosis; Quality of Life; Stomach Neoplasms | 2013 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
A pilot study of combination intraperitoneal recombinant human endostatin and chemotherapy for refractory malignant ascites secondary to ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Endostatins; Female; Humans; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Quality of Life; Recombinant Proteins; Treatment Outcome | 2014 |
A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antineoplastic Agents; Ascites; Carboplatin; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression; Humans; Immunohistochemistry; Mice; Ovarian Neoplasms; Paclitaxel; Pregnancy-Associated Plasma Protein-A; Prognosis; Xenograft Model Antitumor Assays | 2015 |
Prolonged response to aflibercept in ovarian cancer relapse: a case report.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carboplatin; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Lymphatic Metastasis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A | 2015 |
[A case of primary peritoneal carcinoma successfully treated using Paclitaxel and Carboplatin chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-125 Antigen; Carboplatin; Female; Humans; Membrane Proteins; Paclitaxel; Peritoneal Neoplasms | 2014 |
[A recurrent gastric cancer with peritoneal metastasis 15 years after distal gastrectomy successfully treated with S-1 and weekly intravenous and intraperitoneal injections of Paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Combinations; Female; Gastrectomy; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Recurrence; Stomach Neoplasms; Tegafur; Time Factors | 2015 |
Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Blood Proteins; Body Temperature; Cell-Free System; Drug Combinations; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Laparoscopy; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Platelet Count; Retrospective Studies; Second-Look Surgery; Serum Albumin; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells.
Topics: Animals; Antineoplastic Agents; Ascites; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transporters; Biological Transport; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Genes, MDR; Humans; Mice; Mice, Inbred C57BL; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel | 2015 |
Elevated alpha1-acid glycoprotein in gastric cancer patients inhibits the anticancer effects of paclitaxel, effects restored by co-administration of erythromycin.
Topics: Animals; Apoptosis; Ascites; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Drug Therapy, Combination; Erythromycin; Humans; Mice; Orosomucoid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Comparative Study of Antitumor Efficiency of Intraperitoneal and Intravenous Cytostatics in Experimental Rats with Disseminated Ovarian Cancer.
Topics: Adenocarcinoma, Papillary; Animals; Antineoplastic Agents; Ascites; Cisplatin; Female; Injections, Intraperitoneal; Injections, Intravenous; Melphalan; Mitomycin; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Rats; Survival Analysis; Treatment Outcome; Triazines | 2017 |
[Analysis of 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel in Advanced Gastric Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Stomach Neoplasms | 2016 |
The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Female; Granulosa Cell Tumor; Humans; Ovarian Neoplasms; Paclitaxel | 2008 |
[Favourable course of persisting malignant ascites].
Topics: Ascites; Breast Neoplasms; Carboplatin; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Liver Neoplasms; Middle Aged; Mistletoe; Paclitaxel; Phytotherapy; Plant Extracts; Treatment Outcome | 2009 |
Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally.
Topics: Animals; Ascites; Blood Cell Count; Body Weight; Carboplatin; Female; Gene Expression Regulation, Neoplastic; Genetic Therapy; Injections, Intraperitoneal; Interleukin-12; Mice; Mice, Inbred C57BL; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Survival Analysis; Tumor Burden; Viruses | 2009 |
Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Ascites; Biological Transport; Carcinoma, Hepatocellular; Cell Line, Tumor; Docetaxel; Female; Glycerol; Injections, Intraperitoneal; Liver Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polysorbates; Rats; Surface-Active Agents; Taxoids; Tissue Distribution | 2010 |
KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Ascites; Caspase 3; Caspase 7; Caspase 9; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Female; Genes, Reporter; Humans; Inhibitory Concentration 50; Kinesins; Luciferases; Organ Culture Techniques; Ovarian Neoplasms; Paclitaxel; Thiadiazoles; Time Factors; Transfection | 2009 |
Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Recurrence; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Analysis; Tegafur; Tomography, X-Ray Computed | 2010 |
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
Topics: Animals; Antigens, CD; Ascites; Cadherins; Cell Adhesion; Cell Line, Tumor; Drug Synergism; Endothelial Cells; Female; Humans; Interleukin-6; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Receptors, Interleukin-6; Recombinant Fusion Proteins; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2011 |
Differential effect of intraperitoneal albendazole and paclitaxel on ascites formation and expression of vascular endothelial growth factor in ovarian cancer cell-bearing athymic nude mice.
Topics: Albendazole; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Female; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tubulin Modulators; Vascular Endothelial Growth Factor A | 2011 |
[Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Quality of Life; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Blotting, Western; Carboplatin; Cell Line, Tumor; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, SCID; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays | 2012 |
Effects of Taxol on ascites cytology from a patient with fallopian tube carcinoma: report of a case with ultrastructural studies.
Topics: Antineoplastic Agents, Phytogenic; Ascites; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Humans; Microscopy, Electron; Middle Aged; Mitosis; Paclitaxel; Pleural Effusion | 2002 |
[Effective weekly paclitaxel administration for gastric cancer with malignant ascites--a case report].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Signet Ring Cell; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Paclitaxel; Stomach Neoplasms; Treatment Outcome | 2002 |
Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Ascites; Carcinoma; Cell Division; Combined Modality Therapy; Endothelial Growth Factors; Female; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Neutralization Tests; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
[A case responding to weekly paclitaxel (TXL) therapy as third line chemotherapy for scirrhous type gastric cancer].
Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Agents, Phytogenic; Ascites; Drug Administration Schedule; Female; Humans; Paclitaxel; Pleural Effusion; Stomach Neoplasms | 2003 |
[A patient with advanced gastric cancer that response remarkably to combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur; Treatment Outcome | 2003 |
[A case of advanced gastric cancer treated with weekly paclitaxel with measurement of paclitaxel concentrations in blood and ascites].
Topics: Aged; Antineoplastic Agents, Phytogenic; Ascites; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Paclitaxel; Stomach Neoplasms | 2003 |
Bikunin plus paclitaxel markedly reduces tumor burden and ascites in mouse model of ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Enzyme-Linked Immunosorbent Assay; Female; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Tissue Distribution; Trypsin Inhibitor, Kunitz Soybean | 2004 |
Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Ascites; Docetaxel; Erythrocytes; Excipients; Female; Glycerol; In Vitro Techniques; Injections, Intraperitoneal; Paclitaxel; Permeability; Pharmaceutical Vehicles; Polysorbates; Rats; Surface-Active Agents; Taxoids; Time Factors; Tissue Distribution | 2004 |
Eosinophilic ascites: taxol-induced hypersensitivity?
Topics: Antineoplastic Agents, Phytogenic; Ascites; Drug Hypersensitivity; Eosinophilia; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2004 |
[A case report of unresectable gastric cancer that responded to 5-FU plus paclitaxel (FT) therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Fluorouracil; Humans; Jaundice, Obstructive; Male; Middle Aged; Paclitaxel; Stomach Neoplasms | 2004 |
[A case of recurrent gastric cancer with malignant ascites responding dramatically to chemotherapy with paclitaxel infused systemically and intraperitoneally].
Topics: Aged; Antineoplastic Agents, Phytogenic; Ascites; Drug Administration Schedule; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms | 2004 |
[A case report of recurrent gastric cancer in which combination chemotherapy with paclitaxel and 5-fluorouracil made for successful biliary stenting and improvement in QOL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Biliary Tract; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Fluorouracil; Gastrectomy; Humans; Infusions, Intravenous; Infusions, Parenteral; Jaundice, Obstructive; Lymph Node Excision; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stents; Stomach Neoplasms | 2005 |
Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids.
Topics: Antineoplastic Agents; Ascites; Blotting, Western; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Doxorubicin; Flavonoids; Humans; Neoplasms; Paclitaxel; Piperidines; Pleural Effusion, Malignant; Proto-Oncogene Proteins c-bcl-2; Time Factors; Tumor Cells, Cultured | 2005 |
[An unresectable advanced gastric cancer with Virchow's metastasis, carcinomatous ascites and rectal stenosis, effectively managed with combined chemotherapy of biweekly paclitaxel and TS-1].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Signet Ring Cell; Constriction, Pathologic; Drug Administration Schedule; Drug Combinations; Female; Humans; Lymphatic Metastasis; Oxonic Acid; Paclitaxel; Peritonitis; Pyridines; Rectal Diseases; Stomach Neoplasms; Tegafur | 2005 |
Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascites; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Mice; Mice, Nude; Necrosis; Neoplasm Metastasis; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
[A case of ascities decrease in malignant peritoneal mesothelioma by weekly intra-peritoneal administration of cisplatin and paclitaxel].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Humans; Infusions, Parenteral; Male; Mesothelioma; Middle Aged; Paclitaxel; Peritoneal Neoplasms | 2005 |
[A case of intraperitoneal paclitaxel administration in a gastric cancer patient with severely impaired renal function].
Topics: Antineoplastic Agents, Phytogenic; Ascites; Female; Humans; Infusions, Parenteral; Kidney Diseases; Middle Aged; Paclitaxel; Stomach Neoplasms | 2005 |
[An effective weekly paclitaxel administration for gastric cancer with malignant ascites--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Ascites; Drug Administration Schedule; Female; Humans; Paclitaxel; Remission Induction; Stomach Neoplasms | 2005 |
[Effective TS-1+paclitaxel administration for gastric cancer with malignant ascites--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Male; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
Inhibition of tumor metastasis in vivo by combination of paclitaxel and hyaluronic acid.
Topics: Amino Acid Sequence; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Blood Proteins; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Movement; Electrophoresis, Gel, Two-Dimensional; Female; Hyaluronic Acid; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Neoplasm Metastasis; Paclitaxel; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Analysis; Swine; Treatment Outcome; Uterine Cervical Neoplasms | 2006 |
Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Ascites; Ascitic Fluid; Humans; Paclitaxel; Peritonitis; Stomach Neoplasms; Time Factors | 2006 |
Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Ascites; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Female; Gene Expression Regulation; In Situ Nick-End Labeling; Lymph Nodes; Lymphatic Vessels; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Proliferating Cell Nuclear Antigen; Rats; Rats, Inbred F344; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Xenograft Model Antitumor Assays | 2007 |
[A case of advanced gastric cancer with malignant ascites responding to weekly paclitaxel therapy].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Agents, Phytogenic; Ascites; Drug Administration Schedule; Female; Humans; Hydronephrosis; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms | 2006 |
[A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Ascites; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pylorus; Stomach Neoplasms; Tegafur | 2006 |
[A case of complete remission of carcinomatous ascites refractory for TS-1 monotherapy treated with TS-1 plus paclitaxel combined therapy for gastric cancer].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-19-9 Antigen; Female; Gastrectomy; Humans; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Tegafur | 2006 |
[A case report of advanced gastric cancer with carcinomatous ascites successfully treated by outpatient chemotherapy].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms; Taxoids; Tegafur | 2007 |
[Weekly paclitaxel therapy effective for gastric cancer with obstructive jaundice due to peritoneal dissemination--a case report].
Topics: Antineoplastic Agents, Phytogenic; Ascites; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Jaundice, Obstructive; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms | 2007 |
[A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Fluorouracil; Gastroscopy; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Pyloric Stenosis; Quality of Life; Stomach Neoplasms; Survivors | 2007 |
[Efficacy of S-1 combined with weekly Paclitaxel for gastric cancer with cancerous ascites].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
Drug release mechanism of paclitaxel from a chitosan-lipid implant system: effect of swelling, degradation and morphology.
Topics: Animals; Ascites; Chemistry, Pharmaceutical; Chitosan; Drug Delivery Systems; Drug Implants; Female; Humans; Lipids; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Paclitaxel; Prostheses and Implants | 2008 |
Highly elevated serum CA 125 in a lady with ascites and retroperitoneal mass--a diagnostic dilemma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-125 Antigen; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Paclitaxel; Prednisone; Radiography, Abdominal; Retroperitoneal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2008 |
Primary peritoneal serous papillary carcinoma: clinical and laboratory characteristics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Ascites; CA-125 Antigen; Carboplatin; Cisplatin; Constipation; Cystadenocarcinoma, Serous; Female; Gynecologic Surgical Procedures; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Weight Gain | 2008 |
Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Ascites; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids; Transplantation, Heterologous | 1994 |
Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Ascites; Breast Neoplasms; Docetaxel; Edema; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pleural Effusion; Taxoids; Treatment Failure; Treatment Outcome | 1997 |
Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Combined Modality Therapy; Female; Humans; Mesothelioma; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 1999 |
Dermatomyositis and peritoneal papillary serous carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Ascites; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Dermatomyositis; Female; Humans; Hysterectomy; Laparoscopy; Laparotomy; Mucin-1; Paclitaxel; Peritoneal Neoplasms; Pleural Effusion | 1999 |